Ritu Walia1, Sachin Kunde, Lori Mahajan. 1. aDepartment of Pediatric Gastroenterology, West Virginia University, Charleston, West Virginia bDepartment of Pediatric Gastroenterology, Helen DeVos Children's Hospital, Grand Rapids, Michigan cDepartment of Pediatric Gastroenterology, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: The use of transplanted fecal material for the treatment of diarrheal illness dates back to the fourth-century China. While fecal microbiota transplant has gained increasing popularity over the past 50 years for the treatment of refractory Clostridium difficile infections (RCDIs) in adults, it has only been recently utilized in children. The purpose of this article is to review the use of fecal microbiota transplant (FMT) in the treatment of pediatric RCDIs. RECENT FINDINGS: Minimal pediatric data, including few case reports and series, document the successful use of FMT for treatment of RCDI in the past 2 years. Patients in these reports included otherwise healthy children, those with inflammatory bowel disease as well as significantly immunocompromised children. Donor fecal infusion via nasogastric tube, gastroscope or colonoscope in children aged 16 months and older demonstrated a high rate of symptom resolution and organism eradication. No complications to date have been reported in children who have undergone FMT. SUMMARY: FMT is emerging as a well-tolerated and effective treatment for RCDI in not only adults but also children.
PURPOSE OF REVIEW: The use of transplanted fecal material for the treatment of diarrheal illness dates back to the fourth-century China. While fecal microbiota transplant has gained increasing popularity over the past 50 years for the treatment of refractory Clostridium difficile infections (RCDIs) in adults, it has only been recently utilized in children. The purpose of this article is to review the use of fecal microbiota transplant (FMT) in the treatment of pediatric RCDIs. RECENT FINDINGS: Minimal pediatric data, including few case reports and series, document the successful use of FMT for treatment of RCDI in the past 2 years. Patients in these reports included otherwise healthy children, those with inflammatory bowel disease as well as significantly immunocompromised children. Donor fecal infusion via nasogastric tube, gastroscope or colonoscope in children aged 16 months and older demonstrated a high rate of symptom resolution and organism eradication. No complications to date have been reported in children who have undergone FMT. SUMMARY: FMT is emerging as a well-tolerated and effective treatment for RCDI in not only adults but also children.
Authors: William M Tauxe; John P Haydek; Paulina A Rebolledo; Emma Neish; Kira L Newman; Angela Ward; Tanvi Dhere; Colleen S Kraft Journal: Therap Adv Gastroenterol Date: 2015-12-31 Impact factor: 4.409